Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD5-2 is a 20-amino acid peptide derived from the second scavenger receptor cysteine-rich (SRCR) domain of the human CD5 surface glycoprotein. CD5 is a well-known lymphocyte receptor that modulates T-cell and B-cell activation and survival. The CD5-2 peptide was specifically designed to mimic the binding interface of the CD5 ectodomain, allowing it to competitively inhibit the interaction between CD5 and its ligands, such as CD5-like protein (CD5L, also known as AIM or Sp-alpha). Preclinical research has demonstrated that CD5-2 possesses significant anti-inflammatory and immunomodulatory properties. It has been investigated primarily as a therapeutic candidate for the treatment of severe inflammatory conditions, including sepsis and systemic inflammatory response syndrome (SIRS), where it appears to reduce the production of pro-inflammatory cytokines and improve survival rates in animal models. The peptide is also used as a research tool to study the structural biology and signaling pathways associated with the CD5 receptor.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CD5-2.